Write your message
Volume 3, Issue 3 (Summer 2018)                   J Obstet Gynecol Cancer Res 2018, 3(3): 123-128 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Aminimoghaddam S, Abolghasem N, Ashraf- Ganjooie T. New Management of Gestational trophoblastic diseases; A Continuum of Moles to Choriocarcinoma: A Review Article. J Obstet Gynecol Cancer Res. 2018; 3 (3) :123-128
URL: http://jogcr.com/article-1-211-en.html
1- Obstetrics & Gynaecology Ward, 2nd Floor, Emam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Madani Street, Tehran, Iran
Abstract:   (769 Views)
Introduction Gestational trophoblastic diseases (GTD) is the only group of female reproductive neoplasms derived from paternal genetic material (Androgenic origin). GTD is a continuum from benign to malignant; molar pregnancy is benign, but choriocarcinoma is malignant. Approximately 45% of patients have metastatic disease when Gestational trophoblastic neoplasia (GTN) is diagnosed. GTN is unique in women malignancies because it arises from trophoblast but not from genital organs. It is curable with chemotherapy, low-risk GTN completely response to single-agent chemotherapy and does not require histological confirmation. In persistent GTN, clinical staging and workup of metastasis should be performed. The aim of the present study was to review the new management of GTD.
Conclusion In the case of brain, liver, or renal metastases, any woman of reproductive age who presents with an apparent metastatic malignancy of unknown primary site should be screened for the possibility of GTN with a serum HCG level. Excisional biopsy is not indicated to histologically confirm the diagnosis of malignant GTN if the patient is not pregnant and has a high HCG value. Given the vascular nature of these lesions, a biopsy can have significant morbidity. In every woman with abnormal bleeding or neurologic symptom without documented reason, the probability of malignant GTN should be in mind and determination of HCG titer is recommended. In selected cases with low-risk GTN, repeat curettage is done to reduce the need for chemotherapy courses. In recent years personalized medicine is encouraged for treatment of GTN.
Full-Text [PDF 459 kb]   (362 Downloads)    
Systematic Review: Review | Subject: General
Received: 2018/03/13 | Accepted: 2018/04/29 | Published: 2018/09/22

Add your comments about this article : Your username or Email:

© 2020 All Rights Reserved | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.